EBS FY 2018 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

FY 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$782M+39.5% YoY

Gross Profit

$320M41.0% margin

Operating Income

$90M11.5% margin

Net Income

$63M8.0% margin

EPS (Diluted)

$1.22

Cash Flow

Operating Cash Flow

$42M

Free Cash Flow

-$30M

Stock-Based Comp.

$23M

Balance Sheet

Total Assets

$2.2B

Total Liabilities

$1.2B

Stockholders' Equity

$1.0B

Cash & Equivalents

$112M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$782M	$561M	+39.5%
Gross Profit	$320M	$284M	+13.0%
Operating Income	$90M	$124M	-27.8%
Net Income	$63M	$83M	-24.1%